Thursday, AbbVie Inc. (ABBV) reported positive results from the Phase 3b/4 LEVEL UP study comparing the effectiveness and safety of its drug, Upadacitinib/Rinvoq, with Regeneron Pharmaceuticals and Sanofi's drug, Dupilumab/Dupixent, for moderate-to-severe atopic dermatitis in adults and adolescents.

周四，AbbVie Inc.（ABBV）报告了3b/4期升级研究的阳性结果，该研究比较了其药物Upadacitinib/Rinvoq与Regeneron Pharmaceuticals和赛诺菲药物Dupilumab/Dupixent治疗成人和青少年中度至重度特应性皮炎的有效性和安全性。

The study showed that Rinvoq demonstrated better efficacy than Dupixent in achieving the primary endpoint of a 90% or greater reduction in EASI 90 and WP-NRS of 0/1 at week 16. Additionally, Rinvoq outperformed Dupixent in all secondary endpoints, including rapid near-complete skin clearance and reduced itch.

该研究表明，Rinvoq在第16周达到EASI 90和WP-NRS降低90%或更大的主要终点方面比Dupixent表现出更好的疗效。此外，Rinvoq在所有次要终点均优于Dupixent，包括快速接近完全的皮肤清除和减少瘙痒。

The company plans to present the LEVEL UP study results at an upcoming medical congress. For comments and feedback contact: editorial@rttnews.comBusiness News.

该公司计划在即将举行的医学大会上介绍这一升级研究结果。如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻。

Biotech Stocks Facing FDA Decision In April 2024

2024年4月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision in March 2024

2024年3月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In November 2023

2023年11月美国食品和药物管理局（FDA）决定生物技术股